Interim Guidance for the use of Monoclonal Antibodies for Treatment of COVID-19
(Posted January 15, 2021, Updated May 18, 2021)

Monoclonal antibodies are proteins made by immune cells in response to pathogens. They work by binding to viral targets that are used to enter cells and inhibit infection. Patients who are hospitalized with COVID-19 have been found to have high viral loads and thus, monoclonal antibodies were developed to reduce viral burden based on the hypothesis that reducing the amount of virus would lead to clinical improvement.

Key Facts

- **As of May 14th, 2021, the FDA has expanded the definition of who is considered high-risk for progression to severe COVID-19, making more patients potentially eligible for treatment with monoclonal antibodies.**
- Currently, two monoclonal antibody products are available under emergency use authorization (EUA) from the FDA for the treatment of mild to moderate COVID-19:
  - Eli Lilly’s bamlanivimab/etesevimab combination therapy
  - Regeneron’s REGN-COV2 (casirivimab/imdevimab) combination therapy
  - Note: the EUA for bamlanivimab administered alone was revoked in April 2021 due to its ineffectiveness against certain circulating variants of the SARS-CoV-2 virus
- These monoclonal antibody combination products are currently authorized for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive test results of direct SARS-CoV-2 viral testing and who are at high risk for progressing to severe COVID-19 and/or hospitalization.
- The National Institutes of Health (NIH) COVID-19 Treatment Guidelines Panel now strongly recommends the use of bamlanivimab/etesevimab or casirivimab/imdevimab to treat outpatients with mild to moderate COVID-19 who are at high risk of clinical progression.
- Both bamlanivimab/etesevimab and casirivimab/imdevimab are administered via intravenous infusion followed by continued observation for one hour, with an estimated real-world treatment time of two to three hours.
- Anyone 65 years or older with mild to moderate COVID-19 (i.e. not hospitalized and not requiring oxygen due to COVID-19) is considered high risk for progression to severe COVID-19 per the EUA. Thus, monoclonal antibody therapies may be especially useful for skilled nursing and assisted living facilities.
- Monoclonal antibodies for the treatment of COVID-19 should be given to eligible patients within 10 days of symptom onset.
- Monoclonal antibody therapies have a rare risk of serious hypersensitivity reaction, including anaphylaxis.
Monoclonal antibody therapies for COVID-19 have been purchased by the federal government and are available to NC providers at no cost through the contracted distributor AmerisourceBergen. Providers can bill Medicare for the administration fee associated with monoclonal antibody infusions.

**FDA Emergency Use Authorization (EUA)**

The FDA has issued EUA for monoclonal antibody therapies for use in high-risk outpatients with COVID-19. Note that an EUA is not an approval but a determination that potential benefits outweigh potential risks. Bamlanivimab/etesevimab and casirivimab/imdevimab are monoclonal antibody therapies that work directly to neutralize the SARS-CoV-2 virus in the body and may decrease the incidence of ED visits and hospitalizations in patients at greatest risk for progression to severe disease. Under the EUAs, adults and pediatric patients (age 12-17 years and weighing at least 40 kg) with mild and moderate COVID-19 who are at high-risk of progressing to severe disease and/or hospitalization are eligible of treatment. These therapies must be administered within 10 days of symptom onset and ideally administered as soon as possible following a positive viral test for COVID-19. The following medical conditions or factors may place patients at higher risk of progression to severe COVID-19:

- Older age (for example age > 65 years of age)
- Obesity or being overweight (for example, adults with BMI > 25 kg/m², or if age 12-17, have BMI ≥ 85th percentile for their age and gender based on CDC growth charts, [https://www.cdc.gov/growthcharts/clinical_charts.htm](https://www.cdc.gov/growthcharts/clinical_charts.htm))
- Pregnancy
- Chronic kidney disease
- Diabetes
- Immunosuppressive disease or immunosuppressive treatment
- Cardiovascular disease (including congenital heart disease) or hypertension
- Chronic lung diseases (for example, chronic obstructive pulmonary disease, asthma [moderate-to-severe], interstitial lung disease, cystic fibrosis, and pulmonary hypertension)
- Sickle cell disease
- Neurodevelopmental disorders (for example, cerebral palsy) or other conditions that confer medical complexity (for example, genetic or metabolic syndromes and severe congenital anomalies)
- Having a medical-related technological dependence (for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19))

The EUA also acknowledges that authorization of these products is not limited to the medical conditions or factors listed above. Other factors (such as race or ethnicity) may also place patients at high risk for progression to severe disease. Healthcare providers should consider the benefit-risk for an individual patient when making treatment decisions. Please see CDC’s website: [https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html](https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html) for more information on medical conditions or factors associated with increased risk for progression to severe COVID-19.
The Therapies

Note: As of April 16th, 2021 the FDA has revoked the EUA for Bamlanivimab administered alone. The full FDA statement regarding the revocation of the EUA can be found here. Providers who are using monoclonal antibodies to treat COVID-19 patients should switch to using one of the combination therapies listed below that remain available via EUA.

1. Casirivimab and Imdevimab (REGEN-COV™)

On November 21st, 2020 the FDA issued an EUA for casirivimab and imdevimab, which is manufactured by Regeneron and is given as a single infusion. Casirivimab and imdevimab are two recombinant human monoclonal antibodies that bind to non-overlapping epitopes of the spike protein receptor binding domain of SARS-CoV-2. The EUA was based on an interim analysis of Phase 1/2 randomized, double-blinded, placebo-controlled trial in 799 non-hospitalized adults with mild to moderate COVID-19 symptoms. Per the EUA: “For patients at high risk for disease progression, hospitalizations and emergency room visits occurred in 3% of casirivimab and imdevimab-treated patients on average compared to 9% in placebo-treated patients.” The safety in the antibody group was similar to the placebo group. The published NEJM research paper is found here.

2. Bamlanivimab and Etesevimab

On February 9th, 2021, the FDA issued an EUA for the combination of bamlanivimab and etesevimab which is manufactured by Lilly and is given as a single infusion. Bamlanivimab and Etesevimab are monoclonal antibodies that are specifically directed against the spike protein of SARS-CoV-2, designed to block the virus’ attachment and entry into human cells. This EUA is based on analysis of the BLAZE-1 phase 2/3, randomized, double-blind, placebo-controlled trial in non-hospitalized adults with mild to moderate COVID-19 symptoms who were at high risk for progressing to severe COVID-19. Data from the clinical trial shows an 87% reduction of hospitalization in the bamlanivimab 700 mg/etesevimab 1,400 mg group when compared to placebo. The safety in the antibody group was similar to the placebo group. Clinical trial data can be found in section 18 of the EUA documentation here.

Monoclonal Antibodies and SARS-CoV-2 Variants

As SARS-CoV-2 viral variants continue to be identified and quantified across the country, the FDA, CDC and the National Institutes of Health (NIH) are working together to monitor the impacts they may have on the use of monoclonal antibody therapies authorized for emergency use. Recently the FDA updated the authorized “Fact Sheet for Healthcare Providers” for all monoclonal antibody products currently authorized for use (bamlanivimab with etesevimab and casirivimab with imdevimab). These fact sheets contain a section with information related to antiviral resistance for each product. Providers are encouraged to reference the variant information found in section 15 of these fact sheets as well as
CDC’s information showing proportions of SARS-CoV2 variants of concern by state and the number of COVID-19 cases caused by variants when making treatment decisions.

Current available data shows that bamlanivimab administered alone may not be effective against several SARS-CoV-2 variants consistently increasing in prevalence in the United States. Given this information, the FDA revoked the EUA for bamlanivimab administered alone on April 16, 2021.

Obtaining Monoclonal Antibody Products in North Carolina

Allocation and distribution of COVID-19 monoclonal antibody products are controlled by the United States Department of Health and Human Services (US HHS). As of February 19th, US HHS has moved to a direct ordering process for acquiring monoclonal antibodies. Any interested provider, who can meet the requirements of the EUA, can order product as needed directly from AmerisourceBergen using this special form: https://app.smartsheet.com/b/form/255d164d67834793b4ab549e160941e8.

US HHS has ceased distribution of bamlanivimab alone, which is no longer authorized for emergency use. The combination products casirivimab/imdevimab and bamlanivimab/etesevimab remain available for distribution. Providers can also order etesevimab alone to be paired with their existing bamlanivimab inventory to be administered as the authorized combination therapy. Etesevimab is not authorized to be administered alone for the treatment of COVID-19.

Providers receiving and administering COVID-19 monoclonal antibody therapeutics are required to report inventory and administration data on a weekly basis. Upon placing their first order, new providers will receive an email from protect-noreply@hhs.gov with instructions for how to create a TeleTracking account which is the system US HHS uses to collect inventory reports.

Providers looking to refer patients to an existing COVID-19 monoclonal antibody infusion site can use the National Infusion Center Association (NICA) COVID-19 Infusion Center Locator Tool to find North Carolina providers currently administering monoclonal antibodies.

Federal Monoclonal Antibody Call Center

The federal government has established a call center where patients and/or providers can get more information about monoclonal antibody treatments or identify an infusion center in their area.


Additional Resources:

FDA Letter revoking the EUA for Bamlanivimab

NIH COVID-19 Treatment Guidelines Panel statement regarding the use of monoclonal antibodies

Casirivimab/Imdevimab EUA Fact Sheet for Health Care Providers

Casirivimab/Imdevimab EUA Fact Sheet for Patients, Parents and Caregivers
Casirivimab/Imdevimab EUA Fact Sheet for Patients, Parents and Caregivers (Spanish)


HHS ASPR’s Casirivimab/Imdevimab website

Bamlanivimab/Etesevimab EUA Fact Sheet for Health Care Providers

Bamlanivimab/Etesevimab EUA Fact Sheet for Patients, Parents and Caregivers

Bamlanivimab/Etesevimab EUA Fact Sheet for Patients, Parents and Caregivers (Spanish)

Frequently Asked Questions on the Emergency Use Authorization for bamlanivimab/etesevimab

Centers for Medicare & Medicaid Services (CMS) Monoclonal Antibody COVID-19 Infusion Guidance

National Infusion Center Association COVID-19 Antibody Therapies Resource Center

For more information, please contact Tim Davis (tim.davis@dhhs.nc.gov).

Staying apart brings us together. Protect your family and neighbors. #StayStrongNC

Learn more at nc.gov/covid19.